Search

Displaying results 3631 - 3640 of 4359 in total
  1. Drug

    PM02734

    go.drugbank.com/drugs/DB05158
    Investigational

    PM02734 as a new antiproliferative drug demonstrating activity against a broad spectrum of tumor types: breast, colon, pancreas, lung and prostate, among others.

  2. Drug

    Atipamezole

    go.drugbank.com/drugs/DB11481
    InvestigationalVet approved

    It has also been undergone research as a potential anti-Parkinsonian drug for humans.

  3. Drug

    Sodium tripolyphosphate

    go.drugbank.com/drugs/DB11493
    InvestigationalVet approved

    It is used as a component of a wide range domestic and industrial products, particularly detergents.

  4. Drug

    SD118

    go.drugbank.com/drugs/DB05207
    Experimental

    SD118 was previously under investigation in Japan for a different indication and now, following re-profiling and evaluation in experimental animal models, has demonstrated its potential as a new oral therapy

  5. Drug

    MP4

    go.drugbank.com/drugs/DB05313
    Investigational

    MP4 is a hemoglobin-based oxygen carrier designed to serve as an alternative for blood transfusions.

  6. Drug

    Masoprocol

    go.drugbank.com/drugs/DB00179
    Investigational

    It also serves as an antioxidant in fats and oils. [PubChem]

  7. Drug

    Cyclohexanone

    go.drugbank.com/drugs/DB02060
    Experimental

    Cyclohexanone (also known as oxocyclohexane, pimelic ketone, ketohexamethylene, cyclohexyl ketone or ketocyclohexane) is a six-carbon cyclic molecule with a ketone functional group.

  8. Drug

    Tapentadol

    go.drugbank.com/drugs/DB06204
    ApprovedInvestigational

    Tapentadol is a centrally-acting synthetic analgesic with a dual mechanism of action. It is a mu-opioid receptor agonist that also inhibits norepinephrine reuptake. Tapentadol was first approved by the FDA on November 20, 2008. The exten...

  9. Drug

    Tosedostat

    go.drugbank.com/drugs/DB11781
    Investigational

    It has demonstrated anti-tumour activity in a number of models of cancer, both as a single agent and in synergy with cytotoxic agents such as carboplatin and paclitaxel.

  10. Drug

    CTS-21166

    go.drugbank.com/drugs/DB06073
    Investigational

    CTS-21166 is a small-molecule beta-secretase inhibitor, which is being developed as a disease-modifying treatment for Alzheimer's disease. … In 2008, CoMentis revealed this small compound as a transition-state analog inhibitor (structure is currently undisclosed) with excellent properties in brain penetration, selectivity, metabolic stability